Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 6:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 901 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Once Weekly Clear all

Conditions: Multiple Sclerosis
Interventions: Ozanimod, Interferon beta-1a, Placebo to ozanimod, Placebo to interferon beta-1a; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 40
States / cities: Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 35 more

Conditions: Neoplasms
Interventions: Curcumin, Placebo; Drug
Lead sponsor: Lisa Flowers; Other
Eligibility: 21 Years and older · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Healthy, Dermatitis, Atopic
Interventions: LY3844583, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Glendale, California

Conditions: Obese Adults
Interventions: VK2735 Drug, Placebo; Drug
Lead sponsor: Viking Therapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Lake Forest, California • Miami, Florida

Conditions: Hepatitis C, HCV, Chronic Hepatitis C Infection, Hepatitis C Genotype 1
Interventions: ABT-450, ABT-072, ABT-333, Ritonavir, Peginterferon alpha-2a, Ribavirin, Placebo; Drug · Other
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 25
States / cities: Phoenix, Arizona • Anaheim, California • La Jolla, California + 19 more

Conditions: Parkinson's Disease
Interventions: Vitamin D3, Vitamin D3 - high dose, Placebo; Dietary Supplement
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Mucocutaneous Lymph Node Syndrome, Kawasaki Disease
Interventions: Etanercept, Placebo; Drug
Lead sponsor: Michael Portman; Other
Eligibility: 2 Months to 20 Years
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 7
States / cities: New Hyde Park, New York • New York, New York • The Bronx, New York + 4 more

Conditions: brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer
Interventions: cholecalciferol, placebo; Dietary Supplement · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 360
States / cities: Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 230 more

Conditions: Diabetes Mellitus, Type 2
Interventions: CNTO 3649 IV (Healthy participants), CNTO 3649 SC (Healthy participants), CNTO 3649 SC (Diabetic patients), Placebo; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Miramar, Florida • San Antonio, Texas • Tacoma, Washington

Conditions: Hepatitis C
Interventions: Pegylated Interferon Alfa 2a, Telaprevir, Ribavirin, Placebo; Biological · Drug · Other
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,095 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 65
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 48 more

Conditions: Renal Insufficiency
Interventions: Zoledronic Acid, Calcium with vitamin D, Alendronate; Drug · Combination Product
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2014
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Type 2 Diabetes Mellitus
Interventions: tirzepatide, Dulaglutide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 35
States / cities: Mobile, Alabama • Anaheim, California • Fresno, California + 30 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Efpeglenatide SAR439977, Placebo, Background therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 22
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 18 more

Conditions: COVID-19
Interventions: Apixaban 2.5 MG, Apixaban 5MG, Aspirin, Placebo; Drug
Lead sponsor: Frank C Sciurba; Other
Eligibility: 40 Years to 80 Years
Enrollment: 657 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 71
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 51 more

Conditions: Menopause, Irritable Mood
Interventions: Estradiol Patch, 0.1 mg/24 Hours Weekly Transdermal Film, Extended Release, Placebo, Progesterone 200 mg; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 45 Years to 59 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Urinary Tract Infection
Interventions: Lactin-V, Placebo; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Invasive Mould Infection
Interventions: EL219, Active Comparator- IV Antifungal (LAmB or voriconazole); Drug
Lead sponsor: Elion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 11
States / cities: Birmingham, Alabama • Sacramento, California • Augusta, Georgia + 7 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: SAR156597, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years and older
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 18
States / cities: Phoenix, Arizona • Jacksonville, Florida • Loxahatchee Groves, Florida + 15 more

Conditions: Rheumatoid Arthritis
Interventions: Placebo to Upadacitinib, Methotrexate, Placebo to Methotrexate, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 1,002 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 32
States / cities: La Mesa, California • Palm Desert, California • Daytona Beach, Florida + 26 more

Conditions: Rheumatoid Arthritis
Interventions: Abatacept, Methotrexate, Abatacept Placebo, Methotrexate Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 994 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 42
States / cities: Huntsville, Alabama • Glendale, Arizona • Mesa, Arizona + 36 more

Conditions: Diabetes Mellitus, Type 2, Chronic Kidney Disease
Interventions: Semaglutide, Placebo (Semaglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 20
States / cities: Tucson, Arizona • Los Angeles, California • National City, California + 14 more

Conditions: Obesity or Overweight, Type 2 Diabetes Mellitus
Interventions: Placebo, Enicepatide; Combination Product
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 45
States / cities: Guntersville, Alabama • Tucson, Arizona • Irvine, California + 41 more

Conditions: Obesity
Interventions: semaglutide 2.4 mg, semaglutide 2.4 mg (placebo); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Not listed
Enrollment: 407 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 61
States / cities: Montgomery, Alabama • Phoenix, Arizona • Anaheim, California + 52 more

Conditions: Post Traumatic Stress Disorder
Interventions: TSND-201, Placebo; Drug
Lead sponsor: Transcend Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 9
States / cities: Denver, Colorado • Bradenton, Florida • Orlando, Florida + 5 more

Search by objective public record fields.

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)

Topical Curcumin for Precancer Cervical Lesions

A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis

A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072

Clinical Effects of Vitamin D Repletion in Patients With Parkinson's Disease

A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease

S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer

A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus

A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)

Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)

COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80

Estrogen Variability and Irritability During the Menopause Transition

Intravaginal LACTIN-V for Prevention of Recurrent Urinary Tract Infection

Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy

Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis

A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate

Effects of Abatacept in Patients With Early Rheumatoid Arthritis

A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis

An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD